Radiopharm Theranostics ASX RAD 2024 Cancer Research Milestones and 2025 Roadmap

7 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Radiopharm Theranostics (ASX:RAD) is dedicated to developing innovative radiopharmaceutical products for both diagnostic and therapeutic applications, addressing high unmet medical needs. In 2024, the company made significant strides in its cancer research. In this interview, the company’s Managing Director and CEO Mr. Riccardo Canevari shares insights into the key milestones achieved over the past year, including progress in clinical trials, strategic partnerships, and the company’s key priorities and plans for 2025.

#RadiopharmTheranostics #ASXRAD #CancerResearch #Radiopharmaceuticals #OncologyInnovation #ClinicalTrials #ProstateCancerTreatment #NasdaqListing #RAD402 #RAD202 #RadiopharmPipeline #Theranostics #Radiotherapeutics #OncologyBreakthroughs #UnmetMedicalNeeds #CancerTherapeutics #RiccardoCanevari #ASXCompanies #2025Roadmap #OncologyMilestones

World News with in-depth analysis – trusted & transparent! Kalkine Media is on a mission to empower its viewers with quality news coverage from across the globe. Tune into Kalkine Media’s LIVE market news coverage, exclusive corporate interviews, expert talks, and trending stories of the day.

Check out Kalkine Media on mobile and download our app for iPhone and Android. Stay Apprised, Invest Wise!
For Android- bit.ly/3Gqlrpk
For Apple- bit.ly/3WVTMBY

Check out our media Website ???? https://kalkinemedia.com/au
Follow us and stay updated on the Go with the Market Charter ????????
Facebook - https://www.facebook.com/kalkineau/
Twitter - https://twitter.com/kalkineau
LinkedIn - https://www.linkedin.com/company/4829818
Category
Oncology
Be the first to comment

Up Next